NCT05301192 Angiotensin-(1-7) Cardiovascular Effects in Aging

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.

Eligibility Criteria

Inclusion Criteria: * Men and women of all races and ethnicities * Capable of giving informed consent * Fluent in written and spoken English * Age 65-80 years * Body mass index (BMI) between 18.5 and 30 kg/m2 * Normotensive defined as seated blood pressure \<130/80 mmHg and without hypertensive medications * Satisfactory history and physical exam Exclusion Criteria: * Age \< 65 or \> 80 years * Women who are pregnant, nursing, or taking hormone replacement therapy * Decisional impairment * Prisoners * Current or recent (less than 6 months) recreational drug history or excessive alcohol abuse history (greater than 14 drinks per week) * Current smokers * Highly trained athletes * Evidence of type I or type II diabetes (fasting glucose \> 126 mg/dL or use of anti-diabetic medications) * Hypertension or history of serious cardiovascular disease (e.g., myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive

Related Trials